Seronegative spondyloarthropathy-associated inflammatory bowel disease

doi:10.3748/wjg.v29.i3.450

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10307)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

687

WORD

HTML

7886

Figures (1-1)

422

Tables (1-6)

511

Sum=9559

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

178

Download

570

Sum=748

Jan 21, 2023 (publication date) through Jan 1, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jan 21, 2023; 29(3): 450-468
Published online Jan 21, 2023. doi: 10.3748/wjg.v29.i3.450

Table 6 Generic names and currently approved indications of biologics and small molecules from the United States Food and Drug Administration for ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, and inflammatory bowel disease

Category	AS	PsA	JIA¹	UC	CD
Biologics/TNFi
Etanercept	X	X	X
Infliximab	X	X		X	X
Adalimumab	X	X	X	X	X
Golimumab	X	X	X	X
Certolizumab pegol	X	X			X
Biologics/IL-17i
Ixekizumab	X	X
Secukinumab	X	X	X
Biologics/IL-12/23i
Ustekinumab		X	X	X	X
Biologics/IL-23i
Guselkumab		X
Risankizumab		X			X
Biologics/IL-1i
Canakinumab			X
Biologics/IL-6i
Tocilizumab			X
Biologics/anti-integrin mAb
Natalizumab					X
Vedolizumab				X	X
Biologics/anti-CTLA-4 mAb
Abatacept		X	X
Small molecules/JAKi
Tofacitinib	X	X	X	X
Upadacitinib	X	X		X
Small molecules/PDE4i
Apremilast		X
Small molecules/S1PR modulator				X

¹Tumor necrosis factor inhibitor, abatacept, tocilizumab and tofacitinib for polyarticular juvenile idiopathic arthritis (JIA), canakinumab and tocilizumab for systemic JIA, secukinumab and ustekinumab for juvenile psoriatic arthritis, secukinumab for enthesitis-related arthritis.

AS: Ankylosing spondylitis; CD: Crohn’s disease; FDA: United States Food and Drug Administration; IL: Interleukin; JAKi: Janus kinase inhibitor; JIA: Juvenile idiopathic arthritis; PDE4i: Phosphodiesterase 4 inhibitor; PsA: Psoriatic arthritis; S1PR: Sphingosine-1-phosphate receptor; TNFi: Tumor necrosis factor inhibitor; UC: Ulcerative colitis.

Citation: Wang CR, Tsai HW. Seronegative spondyloarthropathy-associated inflammatory bowel disease. World J Gastroenterol 2023; 29(3): 450-468
URL: https://www.wjgnet.com/1007-9327/full/v29/i3/450.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i3.450